Disease-Modifying Treatments for Myasthenia Gravis

CompletedOBSERVATIONAL
Enrollment

167

Participants

Timeline

Start Date

May 7, 2018

Primary Completion Date

January 31, 2021

Study Completion Date

January 31, 2021

Conditions
Neurological DisorderAutoimmune Diseases
Interventions
DRUG

Mycophenolate Mofetil

oral tablets

DRUG

Azathioprine

oral tablet

Trial Locations (19)

14202

University at Buffalo, SUNY, Buffalo

14642

University of Rochester Medical Center, Rochester

15213

University of Pittsburgh, Pittsburgh

19104

University of Pennsylvania, Philadelphia

27599

University of North Carolina at Chapel Hill, Chapel Hill

27710

Duke University, Durham

29425

Medical University of South Carolina, Charleston

33136

Unversity of Miami, Miami

44195

Cleveland Clinic, Cleveland

60612

Rush University Medical Center, Chicago

70121

Ochsner Clinic Foundation, New Orleans

84303

Stanford University, Palo Alto

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

02135

St. Elizabeth's Medical Center, Brighton

05401

University of Vermont - Larner College of Medicine, Burlington

T6G2G3

University of Alberta Hospital, Faculty of Medicine, Edmonton

N6A5A5

London Health Sciences Centre, London

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Patient-Centered Outcomes Research Institute

OTHER

lead

Duke University

OTHER

NCT03490539 - Disease-Modifying Treatments for Myasthenia Gravis | Biotech Hunter | Biotech Hunter